Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double‐blind, multinational, placebo‐controlled phase II/III trial. (January 2014)

• Record Type: Journal Article
• Authors: Vahlquist, A.; Blockhuys, S.; Steijlen, P.; van, K.; Didona, B.; Blanco, D.; Traupe, H.
• Is Part Of: British journal of dermatology. Volume 170:Number 1(2014:Jan.)
• Page Start: 173
• Page End: 181
• Publication Date: 2014-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12626
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="short" xml:lang="en" id="bjd12626-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>What's already known about this topic?</bold> </p> <p> <list id="bjd12626-list-0001" list-type="bullet"> <list-item> <p>Oral liarozole, a retinoic acid metabolism‐blocking agent, may be an alternative to systemic retinoid therapy for patients with lamellar ichthyosis.</p> </list-item> </list> </p> <p> <bold>What does this study add?</bold> </p> <p> <list id="bjd12626-list-0002" list-type="bullet"> <list-item> <p>While the primary endpoint was not met, compared with placebo, once‐daily oral liarozole, 75 or 150 mg, decreased overall severity and scaling, but not erythema and pruritus, and improved Dermatology Life Quality Index in patients with lamellar ichthyosis.</p> </list-item> <list-item> <p>Oral liarozole was well tolerated.</p> </list-item> </list> </p> </abstract>